TScan Therapeutics Inc (TCRX) FinancialsTCRXTScan Therapeutics Inc

Evaluating the bottom line, TScan Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2901.33%, while the net margin is -2888.58%. These profitability ratios, combined with a Return on Equity (ROE) of -95.80%, provide a clear picture of how effectively TCRX converts its operational activities into shareholder value.

In the context of the broader market, TCRX competes directly with industry leaders such as BIVI and PASG. With a market capitalization of $12.63M, it holds a significant position in the sector. When comparing efficiency, TCRX's gross margin of 100.00% stands against BIVI's N/A and PASG's N/A. Such benchmarking helps identify whether TScan Therapeutics Inc is trading at a premium or discount relative to its financial performance.

TScan's financial performance shows a troubling trend with a significant net income loss of $30.4 million in Q2 2026 and a year-over-year revenue decline of 54.5%. The company has maintained a gross margin of 100%, but this is overshadowed by the increasing net income losses and a deteriorating cash position.